MITOTANE Dosage and Mechanism

 Mitotane is a potent cancer medicine which is sold under the brand name LYSODREN. It is used in the treatment of patients with advanced adrenal cortical carcinoma, which is basically a kind of cancer of the outer layer of the adrenal gland. Mitotane is a cytotoxic agent which is used when cancer is inoperable, either functional or non-functional and relapsed. 

Patients with adrenal cortical carcinoma are low; hence it is considered 'rare', and LYSODREN is taken as an orphan medicine for this rare disease. It is available in India, and lysodren's price is economical and can be easily purchased by any authorized supplier against a valid prescription.

How to take Mitotane?

It is available as 500mg tablets, and the initial dose is 2 g to 6 g orally daily, in three or four divided doses, taken with meals containing fatty foods. Increase the dose incrementally to achieve a blood concentration of 14 to 20 mg/l, or as tolerated, and the levels of the active substance in the blood should be monitored frequently. 

Levels above 20 mg/L may cause severe side effects without increasing the medicine's effectiveness. The medicine should be taken till the time it is effective and must be withdrawn if there are any side effects. Indian Pharma Network is among the reliable platforms which facilitate patients' connection with genuine pharmaceutical suppliers, wholesalers, and dealers. To know more details about the cost of MITOTANE in India, contact us at https://indianpharmanetwork.in/contact-us/ 

There is limited information on the use of Lysodren in children, but a daily starting dose of 1.5 to 3.5 g per square meter of body surface area is recommended.

How does MITOTANE work?

Mitotane is a white granular solid composed of clear, colorless crystals. It is tasteless and has a slightly pleasant aromatic odour. Steroid hormones are produced by the cortex of the adrenal gland. When this area develops cancer, levels of these hormones can increase, which causes the symptoms of the disease. The active substance in Lysodren, Mitotane, is thought to work by inhibiting cells in the adrenal gland from working properly and by damaging their mitochondria, there is a reduction in some steroid hormones. It may also alter the breakdown of these hormones. Together, these effects reduce the levels of the hormones in the body, improving the symptoms of the disease. But the exact mechanism of this cytotoxic agent is still unknown. 

Patients taking recommended doses of Mitotane can get benefits fighting against this cancer, and Mitotane 500 mg tablets at economical prices can be obtained through Indian Pharma Network.

For more details about Mitotane, call us at our toll-free number, 18008891064; we will be happy to help you.

Trodelvy for unresectable locally advanced

 "Unresectable locally advanced" is a medical term that describes a situation where a cancerous tumor has grown to a point where it cannot be removed surgically. This can happen because the tumor has grown into or around vital organs, blood vessels, or nerves, making it too risky to attempt surgery.

In these cases, doctors may recommend other treatment options, such as radiation therapy, chemotherapy, targeted therapy, immunotherapy, or a combination of these. The goal of treatment is to shrink the tumor and slow down its growth, alleviate symptoms, improve quality of life, and potentially increase survival.

It is important for patients with unresectable locally advanced cancer to work closely with their healthcare team to determine the best treatment plan for their specific situation. They may also consider seeking a second opinion to ensure they are receiving the most appropriate care.

Trodelvy (sacituzumab govitecan-hziy) is a medication used to treat certain types of cancer. Specifically, it is used to treat adults with metastatic triple-negative breast cancer (TNBC) who have received at least two prior treatments for their disease. It is also used to treat adults with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and either a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor.

Trodelvy is a type of medication called an antibody-drug conjugate. It works by targeting a protein called Trop-2, which is present on the surface of certain cancer cells. The medication is made up of two parts: an antibody that targets the Trop-2 protein and a chemotherapy drug that is attached to the antibody. When the medication attaches to the cancer cell, it releases the chemotherapy drug, which enters the cancer cell and destroys it.

The medication is given as an intravenous (IV) infusion, meaning it is administered directly into a vein over a period of time. The dosage and frequency of treatment will depend on the individual patient's condition and response to treatment.

Like all medications, Trodelvy can cause side effects. Common side effects may include fatigue, nausea, diarrhea, anemia, hair loss, and decreased appetite. More serious side effects may include infections, bleeding, and infusion-related reactions. It is important for patients receiving this treatment to discuss potential side effects with their healthcare provider and report any concerning symptoms promptly.

Triple-negative breast cancer Treatment

 Triple-negative breast cancer (TNBC) is a subtype of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This subtype of breast cancer is more aggressive and difficult to treat than other types of breast cancer, as it does not respond to hormonal therapies or targeted therapies that are effective against ER-positive, PR-positive, or HER2-positive breast cancers.

The treatment of TNBC depends on the stage of cancer and other individual factors such as age, overall health, and personal preferences. The main treatment options for TNBC include:

• Surgery: Surgery is usually the first treatment for TNBC. The aim of surgery is to remove as much cancer as possible. This may involve a lumpectomy (removal of the tumor and a surrounding margin of healthy tissue) or a mastectomy (removal of the entire breast).

• Chemotherapy: Chemotherapy is often used after surgery to reduce the risk of cancer coming back. It may also be used as the primary treatment for TNBC that has spread beyond the breast. Chemotherapy drugs are given intravenously or orally and are designed to kill cancer cells.

• Radiation therapy: Radiation therapy uses high-energy beams to destroy cancer cells. It is often given after surgery to kill any remaining breast or lymph nodes cancer cells. It may also be used to relieve symptoms of advanced TNBC.

• Immunotherapy: Immunotherapy is a targeted therapy that stimulates the immune system to attack cancer cells. Pembrolizumab and atezolizumab are two immunotherapy drugs that have been approved for use in combination with chemotherapy for the treatment of advanced TNBC.

• Clinical trials: There are ongoing clinical trials investigating new treatments for TNBC, including targeted therapies and immunotherapies.

It is essential to work closely with a team of healthcare professionals to determine the best treatment plan for TNBC.

Blincyto Dosage Guidelines

 Blincyto (blinatumomab) is a prescription medication used to treat a specific type of blood cancer called B-cell precursor acute lymphoblastic leukemia (ALL). The dosage of Blincyto may vary based on the patient's body weight and the stage of the disease.

The recommended starting dose of Blincyto is 9 micrograms (mcg) per day, which is delivered through a continuous intravenous infusion (IV) for 28 days. After the first 28 days, the dosage is increased to 28 mcg per day for up to 3 additional cycles of 28 days each.

The dosage of Blincyto may need to be adjusted based on the patient's response to treatment and any side effects they experience. In some cases, the treatment may need to be interrupted or discontinued if severe side effects occur.

It is important to follow the dosing instructions provided by the prescribing healthcare provider and to contact them if you have any questions or concerns about your treatment with Blincyto.

Read -  Blincyto 38.5 mcg for acute lymphoblastic leukemia

Blincyto 38.5 mcg for acute lymphoblastic leukemia

 Blincyto (blinatumomab) is a medication used to treat a specific type of blood cancer called Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

The dose of  Blincyto is based on the patient's weight and is given as a continuous intravenous infusion. The recommended starting dose for adults is 9 mcg/day, which is gradually increased over several days to a target dose of 28 mcg/day. The maximum dose is 42 mcg/day.

However, you mentioned 38.5 mcg," which is not a standard dosage for Blincyto. It's possible that you made a mistake in your question or that you have been prescribed a different dosage based on your individual circumstances.

In any case, it's important to follow your healthcare provider's instructions regarding the dose and administration of Blincyto or any other medication.

BLINCYTO TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA

Blinatumomab (brand name Blincyto) is a medication used to treat a specific type of acute lymphoblastic leukemia (ALL) called Philadelphia chromosome-negative B-cell precursor ALL. Blinatumomab is a type of immunotherapy called a bispecific T-cell engager (BiTE) that works by connecting T-cells to cancer cells, which can help the immune system identify and destroy cancer cells.

Blinatumomab is given as an intravenous infusion over a period of four weeks, followed by a two-week break, and then another four-week infusion cycle. Treatment typically lasts for a total of six cycles. The medication is given in a hospital or infusion center, and patients are closely monitored for potential side effects.

Common side effects of Blinatumomab include fever, fatigue, headache, nausea, vomiting, diarrhea, and decreased appetite. More serious side effects can include infections, allergic reactions, neurological problems, and cytokine release syndrome, which is a potentially life-threatening immune response. Patients receiving Blinatumomab may also experience low levels of certain blood cells, which can increase the risk of bleeding or infections.

Blinatumomab can be a highly effective treatment for certain ALL types, but it is not suitable for everyone. It is important to discuss the potential risks and benefits of this medication with your doctor to determine if it is the right treatment for you.

ENHERTU: Adverse Drug Reactions

The most common side effects of Enhertu, including laboratory abnormalities, in patients with: metastatic breast cancer and HER2-mutant NSCLC were nausea, decreased white blood cell count, decreased hemoglobin, decreased neutrophil count, decreased lymphocyte count, fatigue, decreased platelet count, increased aspartate aminotransferase, vomiting, increased alanine aminotransferase, alopecia, increased blood alkaline phosphatase, constipation, musculoskeletal pain, decreased appetite, hypokalemia, diarrhea, and respiratory infection.

  Gastric cancer was decreased hemoglobin, decreased white blood cell count, decreased neutrophil count, decreased lymphocyte count, decreased platelet count, nausea, fatigue, increased blood alkaline phosphatase, decreased appetite, increased aspartate aminotransferase, increased alanine aminotransferase, diarrhea, hypokalemia, vomiting, constipation, increased blood bilirubin, pyrexia, and alopecia.

Apart from these side effects, the drug is all set to use safely by an expert medical specialist. One can buy ENHERTU 100 mg injection online through various generic medication suppliers like Indian Pharma Network. Visit Contact us: Ikris Pharma Network | Toll-Free:- 1800 889 1064

ENHERTU: Storage and Availability 

The drug Trastuzumab deruxtecan, sold under the brand name Enhertu and is Stored in vials in a refrigerator at 2ºC to 8ºC (36ºF to 46ºF) in the original carton to protect from light until the time of reconstitution. It is made available online to buy. One can easily buy ENHERTU 100mg injection online or by contacting dealers who are recognized generic and innovative medication suppliers. 

Trodelvy Price for 180 MG Vial in India

Trodelvy is made of two different drugs joined together: a monoclonal antibody drug (which attaches to Trop -2 receptors, present on the outside of some cancer cells, and a chemotherapy drug (which stops all cells including unhealthy cells from growing and dividing). The monoclonal antibody drug attaches to the unhealthy cells and then releases the chemotherapy medicine directly into the cell.

Send your inquiry now to buy Trodelvy 180 mg vials online or know more about Trodelvy price (180 mg vial of sacituzumab govitecan) either via Call/WhatsApp: +919310090915, or TOLL-FREE: 1800-889-1064

The well-qualified and dedicated team at Indian Pharma Network provides a quick, predictable response to your quote requests immediately.

All pharmaceutical products – comparator drugs, adjunctive therapies, RLDs, co-meds, and rescue meds, and Exports/Imports drugs – are transported in standard temperature-controlled conditions with active monitoring in order to ensure the integrity of products. Contact us today to get/buy your hard-to-access prescription medicine at the lowest price from India.